Ozempic maker $500b valuation

Pro Search

3 steps completed
Novo Nordisk, the pharmaceutical company that manufactures the diabetes and weight-loss drugs Ozempic and Wegovy, has surpassed a market valuation of $500 billion. This significant valuation is attributed to the soaring demand for these drugs, with Ozempic sales alone accounting for 41% of the company's total sales in 20237. The company's stock price has risen nearly 5%, reaching nearly $114 after releasing better-than-expected quarterly earnings5. The Danish pharmaceutical giant's valuation rose to $506 billion, as reported by CNBC using data from the London Stock Exchange Group35. This surge in valuation has made Novo Nordisk Europe’s biggest drug company5. The company's full-year operating profit jumped by 37% in kroner and 44% at constant exchange rates to 102.6 billion kroner3. Novo Nordisk's success has been fueled by a 154% sales increase in its obesity care products at constant exchange rates3.
what is the market value of novo nordisk before and after the ozempic revolution
what is the revenue of novo nordisk in 2023
what is the net income of novo nordisk in 2023
Ozempic maker Novo Nordisk passes $500 billion market value | Semafor
CHART OF THE DAY: Ozempic maker Novo Nordisk overtakes LVMH to ...
CHART OF THE DAY: Ozempic Maker Novo Nordisk Is Biggest Company in ...
Ozempic Maker Eclipses LVMH As Europe's Most Valuable Company
Ozempic maker Novo Nordisk isn't just Europe's 2nd-most-valuable ...
Ozempic and Wegovy maker Novo Nordisk now worth $500B
View More